Special Issue

Precision Medicine for Retinal Disease

Message from the Guest Editors

Retinal diseases, such as diabetic retinopathy and age-related macular degeneration, to name only the most common, can still cause profound and irreversible visual loss, leading to significant morbidity worldwide. In the abovementioned indications, intravitreal injections of anti-VEGFs, which have obtained regulatory authorizations for more than 10 years, have allowed for a drastic reduction in the rate of blindness and morbidity, but at the cost of frequent visits and treatments during their initial use. The current objective of treatments in retinal pathology is not only to ensure visual recovery but also to limit the therapeutic burden. New treatment protocols have therefore emerged in recent years, making it possible to propose a therapeutic regimen adapted to each retinal disease and to each patient. Nonvascular retinal pathologies have also seen the advent of new precision therapies, such as retinal dystrophies, for which gene therapy allows targeted therapies adapted to each mutation. The future of the management of retinal diseases, whether medical or surgical, has a bright future ahead of it, with the watchword of the personalization of treatment.

Guest Editors

Dr. Sara Touhami

1. Department of Ophthalmology, Pitié Salpêtrière University Hospital, Sorbonne Université, 75013 Paris, France
2. Department of Ophthalmology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Université de Paris, 75010 Paris, France

Dr. Alexandra Miere

Department of Ophthalmology, Creteil Hospital, Paris Est University, Créteil, France

Deadline for manuscript submissions

closed (20 June 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).